Beleodaq® Drug to Treat Rare Form of Non-Hodgkin Lymphoma Receives Accelerated FDA Approval

On July 3, 2014, the U.S. Food and Drug Administration (FDA) approved Beleodaq® (belinostat) as a treatment for Peripheral T-Cell Lymphoma (PTCL). PTCL is a rare and fast-growing type of Non-Hodgkin Lymphoma (NHL) in which the lymph nodes become cancerous. Beleodaq®, which received accelerated approval, is designed to stop enzymes that contribute to T-cells, a […]